Company intelligence / Profile preview

OncoVent

Shenzhen, Guangdong, China

Ownership: Private
Development stage: Other

Overview

Lead program oregovomab (anti-CA125 monoclonal antibody) has demonstrated significant improvements in median progression-free-survival and overall survival in Phase II trials for first-line advanced ovarian cancer, and is in Phase III global multicenter trials. Other assets are at earlier clinical and preclinical stages.[1][2][3]

Therapeutic areas: Oncology
Modalities: Monoclonal antibodyBiologic
Industry: Biotech

Partnerships

Orient EuroPharma (license and distribution agreement for oregovomab in Taiwan, with rights of first refusal for Hong Kong and Macau)[2][3]Cytovance Biologics (CDMO, manufacturing for oregovomab)[2][3]

Beyond the preview

Go deeper on OncoVent.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OncoVent.

Explore the full profile